Posted by Michael Wonder on 19 Sep 2018
NICE encourages further discussions on Kymriah for adult lymphoma
19 September 2018 - CAR-T is too expensive to recommend as a treatment for adults with lymphoma, NICE says in draft guidance today.
However, NICE does recognise that Novartis’ tisagenlecleucel-T, also known as Kymriah, has significant clinical benefits, and would welcome further discussions on its cost-effectiveness.
NICE’s independent technology appraisal committee considered tisagenlecleucel-T for adults who have relapsed or refractory diffuse large B-cell lymphoma after 2 or more lines of systemic therapy.
